Obesity Surgery

, Volume 19, Issue 11, pp 1557–1563 | Cite as

YKL-40 is Elevated in Morbidly Obese Patients and Declines After Weight Loss

  • Moritz Hempen
  • Hans-Peter Kopp
  • Marie Elhenicky
  • Clemens Höbaus
  • Johanna-Maria Brix
  • Renate Koppensteiner
  • Guntram Schernthaner
  • Gerit-Holger SchernthanerEmail author
Clinical Research



Patients suffering from morbid obesity (MO) have an increased cardiovascular morbidity and mortality. This increased cardiovascular burden is believed to be caused by a sub-inflammatory state through an increased secretion of monocyte chemoattractant protein-1 (MCP-1) by the adipose tissue, resulting in insulin resistance (IR) and type 2 diabetes mellitus (T2DM). YKL-40, which is elevated in inflammatory processes in T2DM and IR and in ruptured plaques, might as well be involved in the increased cardiovascular burden of MO patients. The present study aims to study the level of YKL-40 in MO patients before and after weight loss as well as to investigate the relationship between YKL-40, IR, MCP-1, and obesity.


We investigated YKL-40 levels in serum samples of both 17 morbidly obese patients before and after bariatric surgery and 17 healthy controls. YKL-40 levels were determined in serum samples by enzyme-linked immunosorbent assay.


After a mean follow-up of 17.4 months and a mean weight loss of 40 kg through bariatric surgery, YKL-40 levels declined by 30.5% (p = 0.027). Multiple linear regression analysis revealed that only preoperative MCP-1 values remained independently and significantly (p = 0.001) associated with preoperative YKL-40 levels. Moreover, delta (change) homeostasis model assessment of insulin resistance (HOMA-IR) values remained independently and significantly (p = 0.002) associated with delta YKL-40 levels.


We show for the first time that elevated levels of YKL-40 in MO patients decreased after massive weight loss via bariatric surgery. YKL-40 was correlated with HOMA-IR and fasting insulin levels, indicating a role in developing processes of IR and T2DM. The tight association of MCP-1 (plaque development) and YKL-40 (plaque rupture) points to a central role of both proteins, contributing to the increased cardiovascular mortality in MO patients.


YKL-40 Human Morbid obesity Monocyte chemoattractant protein-1 Diabetes mellitus Type 2 Insulin resistance 


  1. 1.
    Stevens J, Cai J, Pamuk ER, et al. The effect of age on the association between body-mass index and mortality. N Engl J Med. 1998;338:1–7.CrossRefGoogle Scholar
  2. 2.
    Fontaine KR, Redden DT, Wang C, et al. Years of life lost due to obesity. JAMA. 2003;289(2):187–93.CrossRefGoogle Scholar
  3. 3.
    Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case–control study. Lancet. 2005;366:1640–9.CrossRefGoogle Scholar
  4. 4.
    Yusuf S, Vaz M, Pais P. Tackling the challenge of cardiovascular disease burden in developing countries. Am Heart J. 2004;148:1–4.CrossRefGoogle Scholar
  5. 5.
    Sjöström L, Narbro K, Sjöström CD, et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007;357:741–52.CrossRefGoogle Scholar
  6. 6.
    Kopp HP, Kopp CW, Festa A, et al. Impact of weight loss on inflammatory proteins and their association with the insulin resistance syndrome in morbidly obese patients. Arterioscler Thromb Vasc Biol. 2003;23:1042–7.CrossRefGoogle Scholar
  7. 7.
    Kopp HP, Krzyzanowska K, Möhlig M, et al. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes (Lond). 2005;29:766–71.CrossRefGoogle Scholar
  8. 8.
    Matsushima K, Larsen CG, DuBois GC, et al. Purification and characterization of a novel monocyte chemotactic and activating factor produced by a human myelomonocytic cell line. J Exp Med. 1989;169:1485–90.CrossRefGoogle Scholar
  9. 9.
    Gerhardt CC, Romero IA, Cancello R, et al. Chemokines control fat accumulation and leptin secretion by cultured human adipocytes. Mol Cell Endocrinol. 2001;175:81–92.CrossRefGoogle Scholar
  10. 10.
    Schernthaner G, Morton JM. Bariatric surgery in patients with morbid obesity and type 2 diabetes. Diabetes Care. 2008;31(Suppl 2):S297–302.CrossRefGoogle Scholar
  11. 11.
    Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004;292:1724–37.CrossRefGoogle Scholar
  12. 12.
    Stamler R, Stamler J, Riedlinger WF, et al. Weight and blood pressure. Findings in hypertension screening of 1 million Americans. JAMA. 1978;240:1607–10.CrossRefGoogle Scholar
  13. 13.
    Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease. Pathophysiology, evaluation, and effect of weight loss. Arterioscler Thromb Vasc Biol. 2006;26:968–76.CrossRefGoogle Scholar
  14. 14.
    de Lemos JA, Morrow DA, Sabatine MS, et al. Association between plasma levels of monocyte chemoattractant protein-1 and long-term clinical outcomes in patients with acute coronary syndromes. Circulation. 2003;107:690–5.CrossRefGoogle Scholar
  15. 15.
    Dahlman I, Kaaman M, Olsson T, et al. A unique role of monocyte chemoattractant protein 1 among chemokines in adipose tissue of obese subjects. J Clin Endocrinol Metab. 2005;90:5834–40.CrossRefGoogle Scholar
  16. 16.
    Ylä-Herttuala S, Lipton BA, Rosenfeld ME, et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A. 1991;88:5252–6.CrossRefGoogle Scholar
  17. 17.
    Takeya M, Yoshimura T, Leonard EJ, et al. Detection of monocyte chemoattractant protein-1 in human atherosclerotic lesions by an anti-monocyte chemoattractant protein-1 monoclonal antibody. Hum Pathol. 1993;24:534–9.CrossRefGoogle Scholar
  18. 18.
    Inoue S, Egashira K, Ni W, et al. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2002;106:2700–6.CrossRefGoogle Scholar
  19. 19.
    Schernthaner GH, Kopp HP, Kriwanek S, et al. Effect of massive weight loss induced by bariatric surgery on serum levels of interleukin-18 and monocyte-chemoattractant-protein-1 in morbid obesity. Obes Surg. 2006;16:709–15.CrossRefGoogle Scholar
  20. 20.
    Johansen JS, Milman N, Hansen M, et al. Increased serum YKL-40 in patients with pulmonary sarcoidosis—a potential marker of disease activity? Respir Med. 2005;99:396–402.CrossRefGoogle Scholar
  21. 21.
    Johansen JS, Christoffersen P, Møller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol. 2000;32:911–20.CrossRefGoogle Scholar
  22. 22.
    Matsumoto T, Tsurumoto T. Serum YKL-40 levels in rheumatoid arthritis: correlations between clinical and laborarory parameters. Clin Exp Rheumatol. 2001;19:655–60.PubMedGoogle Scholar
  23. 23.
    Dupont J, Tanwar MK, Thaler HT, et al. Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol. 2004;22:3330–9.CrossRefGoogle Scholar
  24. 24.
    Johansen JS, Drivsholm L, Price PA, et al. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer. 2004;46:333–40.CrossRefGoogle Scholar
  25. 25.
    Rathcke CN, Johansen JS, Vestergaard H. YKL-40, a biomarker of inflammation, is elevated in patients with type 2 diabetes and is related to insulin resistance. Inflamm Res. 2006;55:53–9.CrossRefGoogle Scholar
  26. 26.
    Nielsen AR, Erikstrup C, Johansen JS, et al. Plasma YKL-40: a BMI-independent marker of type 2 diabetes. Diabetes. 2008;57:3078–82.CrossRefGoogle Scholar
  27. 27.
    Boot RG, van Achterberg TA, van Aken BE, et al. Strong induction of members of the chitinase family of proteins in atherosclerosis: chitotriosidase and human cartilage gp-39 expressed in lesion macrophages. Arterioscler Thromb Vasc Biol. 1999;19:687–94.CrossRefGoogle Scholar
  28. 28.
    Fach EM, Garulacan LA, Gao J, et al. In vitro biomarker discovery for atherosclerosis by proteomics. Mol Cell Proteomics. 2004;3:1200–10.CrossRefGoogle Scholar
  29. 29.
    Kucur M, Isman FK, Karadag B, et al. Serum YKL-40 levels in patients with coronary artery disease. Coron Artery Dis. 2007;18:391–6.CrossRefGoogle Scholar
  30. 30.
    Kastrup J, Johansen JS, Winkel P, CLARICOR Trial Group, et al. High serum YKL-40 concentration is associated with cardiovascular and all-cause mortality in patients with stable coronary artery disease. Eur Heart J. 2009;30:1066–72.CrossRefGoogle Scholar
  31. 31.
    Nøjgaard C, Høst NB, Christensen IJ, et al. Serum levels of YKL-40 increases in patients with acute myocardial infarction. Coron Artery Dis. 2008;19:257–63.CrossRefGoogle Scholar
  32. 32.
    Wittgrove AC, Clark GW, Tremblay LJ. Laparoscopic gastric bypass, Roux-en-Y: preliminary report of five cases. Obes Surg. 1994;4:353–7.CrossRefGoogle Scholar
  33. 33.
    Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412–9.CrossRefGoogle Scholar
  34. 34.
    Nishikawa KC, Millis AJ. gp38k (CHI3L1) is a novel adhesion and migration factor for vascular cells. Exp Cell Res. 2003;287:79–87.CrossRefGoogle Scholar
  35. 35.
    Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–43.CrossRefGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Moritz Hempen
    • 1
  • Hans-Peter Kopp
    • 2
  • Marie Elhenicky
    • 1
  • Clemens Höbaus
    • 1
  • Johanna-Maria Brix
    • 2
  • Renate Koppensteiner
    • 1
  • Guntram Schernthaner
    • 2
  • Gerit-Holger Schernthaner
    • 1
    Email author
  1. 1.Department of Medicine IIMedical University of ViennaViennaAustria
  2. 2.Department of Medicine IRudolfstiftung HospitalViennaAustria

Personalised recommendations